Investment
Features
FeesSafety
Academy
More
Pluang+

Admiral Group directors acquire shares via dividend reinvestment plan on Oct 14, 2026

Company Fundamentals
16 Oct 2026
Na
View Source
Neutral
Admiral Group directors acquire shares via dividend reinvestment plan on Oct 14, 2026

On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at prices around £36.83 to £36.84 on the London Stock Exchange. This move reflects continued insider confidence in the company. The acquisitions were part of a plan initiated in May 2020 and indicate ongoing shareholder engagement by the directors and their associates.

Regarding the recent Director/PDMR shareholding activity, here is Pluang's market snapshot as of Oct 16, 2026 13:11 WIB: Among 142 priced Financials-sector US stocks tradable on Pluang, 118 rose and 23 fell today. Notable movers include Carlyle Group Inc (CG) at USD 36.93 with a 1-day change of +3.24% and a typical hold time of 112 days; Bank of New York Mellon Corp (BNY) at USD 142.06 with a 1-day change of +3.20%, typical hold time of 60 days, and Pluang order activity showing 0% Sell / 100% Buy; and KB Financial Group, Inc. (KB) at USD 120.74 with a 1-day change of +3.20% and a typical hold time of 34 days.

More News

Norsk Hydro to release Q3 2026 results on Oct 23 with live webcast presentation.

Norsk Hydro to release Q3 2026 results on Oct 23 with live webcast presentation.

Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...

Company Fundamentals
Neutral
17 minutes ago
FDA approves Roche’s Enspryng as first at-home treatment for thyroid eye disease

FDA approves Roche’s Enspryng as first at-home treatment for thyroid eye disease

The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...

Market News
Bullish
1 hour ago
Norsk Hydro to release Q3 2026 results on Oct 23 with CEO webinar and Q&A session

Norsk Hydro to release Q3 2026 results on Oct 23 with CEO webinar and Q&A session

Norsk Hydro will publish its third quarter 2026 financial results on October 23 at 07:00 CEST. The report and presentation will be available on their website simultaneously. Following the release, CEO Eivind Kallevik and CFO Trond Olaf Christophersen...

Company Fundamentals
Neutral
4 hours ago
XRP remains 62.5% below its 2018 peak due to supply growth, weak demand, and regulatory issues.

XRP remains 62.5% below its 2018 peak due to supply growth, weak demand, and regulatory issues.

XRP is trading around $1.33, about 62.5% below its January 2018 peak of $3.55, unlike Bitcoin and Ether which have surpassed their previous highs. Analysts attribute XRP's lag to a 63% increase in circulating supply, weak fund inflows, declining trad...

Market News
Bearish
4 hours ago
US population growth slows, boosting demand for Sunbelt real estate and senior housing sectors.

US population growth slows, boosting demand for Sunbelt real estate and senior housing sectors.

US population growth is slowing due to lower birth rates and tighter immigration policies, but rising affluence is increasing per capita real estate demand. This trend benefits sectors like logistics, housing, farmland, and especially senior housing,...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App